Researchers sought to characterize real-world efficacy of repeated ketamine infusions for treatment-resistant bipolar depression assessing symptoms of depression, anxiety, suicidality, and functioning.
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Patients with acute appendicitis between 2000 and 2020 were evaluated for complications on the basis of having a mental health diagnosis.
The study included approximately 400 adults with a history of bipolar I disorder who had a current episode of mania.
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot.
The main focus of the debate surrounding pediatric bipolar disorder pertains to the concept of a prepubertal subtype of the disorder.
This study recruited individuals with BD via advertisements on social media and through the Collaborative RESearch Team to study psychosocial issues in Bipolar Disorder (CREST.BD) website and its mailing list.
The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, respectively.
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
The approval was supported by data from two phase 3 studies that evaluated Caplyta as monotherapy and adjunctive therapy with lithium or valproate in adults with bipolar depression.
